Scientific deep-dive

GLP-1 Pancreatitis and Gallbladder Risk: What the Labels Counted

Two labeled warnings that are not the same kind of problem. Gallbladder disease tracks with rapid weight loss and is well counted; pancreatitis is rarer, was an exclusion criterion in the pivotal trials, and the database studies disagree.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
12 min read·19 citations

Part of Safety and side effects, separated from the headlines

Pancreatitis and gallbladder disease sit next to each other on every GLP-1 side effect list, and they are not the same kind of problem. Gallstones and gallbladder inflammation show up more often on these drugs, and much of that appears to track the speed of the weight loss, though two of the labels say not all of it does. Pancreatitis is rarer, the trial evidence is thin in exactly the group that worries about it most, and the observational studies disagree with each other. Both produce abdominal pain that needs a clinician the same day, not a search engine. Most stomach pain on these drugs is neither, and what separates the ordinary kind from these two is covered in its own guide.

Severe abdominal pain that will not let up, especially pain that spreads through to your back, is an emergency. So is pain in the upper stomach with fever, yellowing of the eyes or skin, or pale, clay-colored stools, which the Medication Guides list as signs of gallbladder trouble. Both are same-day problems. Call your prescriber, an urgent care line, or 911. Do not wait for a message to be answered, and do not read the rest of this page first.

Pancreatitis: what the approved labels commit to

Every approved GLP-1 and dual-agonist label in this class carries a pancreatitis warning, and the four we read carry it in nearly identical words. Wegovy's section 5.2 names acute pancreatitis, including the hemorrhagic and necrotizing forms, and including fatal cases.[1] Then it makes a careful choice of verb.

… observed in patients treated with …
— Wegovy prescribing information, §5.2 Acute Pancreatitis

“Observed in” says who the events happened to. It does not say the drug produced them. The Zepbound, Mounjaro and Ozempic warnings are built the same way.[2] All four also name the same forms of the illness, fatal ones included.[3] A label resting on a causal finding reads differently, and the same document shows you how: a few paragraphs away, the counseling section on thyroid tumors tells prescribers flatly that semaglutide causes them in rodents.[1] That is the verb regulators use when they have the finding. They did not use it here.

The counted numbers behind the warning are small and they do not point one way. In the pooled Zepbound weight-reduction trials, adjudication-confirmed acute pancreatitis occurred in 0.2% of patients on the drug and 0.2% on placebo (0.14 versus 0.15 events per 100 years of exposure).[2] In the tirzepatide diabetes program the same adjudication process found 14 events in 13 treated patients, a rate of 0.23 per 100 years of exposure against 0.11 in comparator arms.[3] Those are the numbers a regulator saw. They are compatible with a small excess and they are compatible with none.

One finding is easy to misread. Both tirzepatide labels report that treatment raises pancreatic enzymes measurably in ordinary use: amylase up by 20% to 25% and lipase by 28% to 35% in the Zepbound weight-reduction pool,[2] and by 33% to 38% and 31% to 42% respectively in the Mounjaro trials.[3] Both labels then state plainly that the clinical significance of such an elevation is unknown when nothing else is wrong. A raised lipase on routine bloodwork is not a diagnosis. Take the question to the clinician who ordered the test. Raised liver enzymes are a separate question, covered in GLP-1 drugs and liver enzymes.

The trials left out the people who most want an answer

If you have had pancreatitis before, the pivotal trial record cannot tell you what happens to you, because you would not have been enrolled in it. The registry eligibility records show this directly. SURMOUNT-1, the 2,539-person tirzepatide obesity trial, lists “History of pancreatitis” flatly among its exclusion criteria.[5][6] SURMOUNT-2 and SURMOUNT-5 exclude a history of chronic or acute pancreatitis in the same terms.[7][8] SELECT, the large semaglutide cardiovascular outcomes trial, excludes chronic pancreatitis and any acute episode in the 180 days before screening.[9]

One caveat. The public registry entry for STEP 1, the semaglutide obesity trial, lists only two exclusion criteria for its main phase, and pancreatitis is not among them.[10] That record is clearly abbreviated, not the full protocol, so we cannot tell you from a primary source whether STEP 1 excluded people with a pancreatitis history. We can tell you that the tirzepatide obesity program and the semaglutide cardiovascular program did.

Randomization gives you the cleanest possible comparison, but it gives it to you about a population that was screened to be low-risk for the exact outcome in question. Nobody hid this. It is standard trial design, and it is the reason the answer for a person with prior pancreatitis has to come from somewhere else.

What the observational studies do and do not settle

Somewhere else means large database studies, which include the excluded people but cannot randomize anyone. They have produced a mixed record, and any page that reports only one of them is cherry-picking.

Observational studies of GLP-1 medication and acute pancreatitis, read in full abstract on August 14, 2026
StudyDesignWhat it found
Faour and colleagues, Veterans Health Administration data, 2025[11]88,972 matched pairs; new users of a GLP-1 versus new users of a DPP-4 inhibitorAcute pancreatitis in 0.31% of GLP-1 users versus 0.24% of comparators, odds ratio 1.28 (95% CI 1.07 to 1.53). The authors call the increase modest and advise vigilance rather than avoidance.
Nieto and colleagues, TriNetX records, 2026[12]20,459 matched pairs with type 2 diabetes, GLP-1 users versus non-usersNo increase in pancreatitis risk, and lower rates of complications and death among those who did develop it. Uncomplicated pancreatitis trended lower without reaching significance.
Crisafulli and colleagues, Annals of Internal Medicine, 2026[13]Head-to-head new-user cohorts, over 130,000 matched pairs across three comparisonsSimilar gastrointestinal safety across dulaglutide, semaglutide and tirzepatide. This design compares the drugs with each other, so it cannot say whether any of them differs from no drug at all.
Postlethwaite and colleagues, Pancreatology, 2025[14]2,245 patients started on a GLP-1 for obesity; case-control49 developed pancreatitis. The strongest predictors were a history of gallstone disease (adjusted odds ratio 2.9) and a prior episode of pancreatitis (4.8), with tobacco use also raising risk.

The last row is the useful one for an individual reader. Whatever the population-level effect turns out to be, the people who went on to have pancreatitis were disproportionately the ones who had already had it, or who had gallstones. Tell a prescriber about either before a first injection. It is a question about your own history, not about the drug.

Regulators looked hard at this class once before. In 2014 staff from the FDA and the European Medicines Agency published a joint assessment of the pancreatic safety of incretin drugs in the New England Journal of Medicine.[15] It is the single most-cited item in this debate, but it is a four-page Perspective piece with no abstract indexed and no open copy we could retrieve, so we point to it without summarizing a conclusion we did not read. It is also twelve years old, and most of the studies on this page did not exist when it was written.

A note on what you are reading elsewhere. The most widely circulated claims-database analysis of gastrointestinal events on GLP-1 medication appeared in JAMA as a Research Letter rather than as a full paper.[16] That format is real research and it is peer reviewed. It is also two pages long, which means far less method detail than a reader comparing it against a 2,539-person trial is likely to assume. Its headline figures, read against people taking bupropion-naltrexone rather than placebo, were a hazard ratio of 9.09 for pancreatitis (confidence interval 1.25 to 66.00), 4.22 for bowel obstruction (1.02 to 17.40) and 3.67 for gastroparesis (1.15 to 11.90), with no significant difference for gallbladder and bile-duct disease.[16] Those intervals are as wide as they look. In the study’s own table, nobody taking semaglutide had a bowel obstruction at all, so that signal comes from liraglutide; the obstruction result lost significance in the authors’ own sensitivity analysis; and gastroparesis was counted from a diagnosis code or a prescription for a gut-motility drug, without a stomach-emptying test.[16]

Gallbladder disease: a different question, a clearer answer

The gallbladder signal is stronger, better counted, and better explained. In the adult weight-reduction trials behind the Wegovy label, gallstones were reported by 1.6% of patients on the injection against 0.7% on placebo, and gallbladder inflammation by 0.6% against 0.2%.[1] The pooled Zepbound weight-reduction trials found gallstones in 1.1% against 1%, inflammation in 0.7% against 0.2%, and gallbladder removal in 0.2% against none.[2] Ozempic's postmarketing section lists cholecystitis and cholecystectomy under hepatobiliary reports.[4]

Pooling helps. A systematic review of 76 randomized trials, with 103,371 patients between them, put the relative risk on GLP-1 treatment at 1.37 for disease of the gallbladder or bile ducts, with risk rising at higher doses and longer durations.[17] The number that matters for anyone taking these drugs to lose weight is the split inside it: the relative risk was 2.29 in the 13 trials run for weight loss and 1.27 in the 63 trials run for diabetes or other conditions, and the difference between those two was itself statistically significant.[17] The trials with more weight loss had more gallbladder disease.

A tirzepatide-only review of nine trials lands in the same place from the other direction. It found no significant association with pancreatitis (relative risk 1.46, confidence interval 0.59 to 3.61) and a significant one with the composite of gallbladder or biliary disease (1.97, 1.14 to 3.42).[18]

Why the mechanism matters to you

Losing weight quickly is an established way to form gallstones, independent of any medication. Bile chemistry shifts, the gallbladder empties less often when there is less fat in the diet to prompt it, and stones form. That is why gallstones are a known complication of very-low-calorie dieting and of bariatric surgery, neither of which involves a GLP-1 at all.

So the likeliest reading is that much of this is a rapid-weight-loss risk that these drugs deliver by being effective, though not all of it: the Wegovy label says the excess gallbladder events remained even after accounting for how much weight people lost.[1] That framing should change what you do with it, but it should not make you dismiss it. A gallstone attack is the same illness whichever route brought it on.

The two labels do not fully agree here, and the disagreement is worth knowing. Wegovy's warning states that the excess over placebo remained once the amount of weight lost had been accounted for, which points at something beyond the weight loss alone.[1] Zepbound's warning makes no such claim: it says the events tracked with weight reduction and stops there.[2] Two manufacturers read their own trial data and wrote different sentences about it. Anyone telling you this question is closed has not read both.

Age changes the picture. In the adolescent trial the label reports cholelithiasis in 3.8% of treated patients aged 12 and over against 0% on placebo, and cholecystitis in 0.8% against 0%. The gallstone figure is more than double the adult rate, and the label says directly that these events were more common in treated adolescents than in treated adults.[1] Anyone weighing this for a teenager is weighing a different risk profile than the adult trials describe.

The symptoms that mean today, not Monday

Both label sets translate the warning into patient-facing language, and the wording barely changes across products. For pancreatitis, Wegovy's counseling section instructs prescribers to describe severe abdominal pain that sometimes travels through to the back. Nausea and vomiting may accompany it, and may not.[1] Mounjaro and Zepbound give prescribers the same script.[2]

  • Severe pain in the stomach area that will not go away, sometimes spreading through to the back. Vomiting may or may not be present. This is the pattern every label describes for pancreatitis. Stop the drug and seek care the same day.
  • Pain in the upper stomach with fever, yellowing of the eyes or skin, or clay-colored stools. The Medication Guides list these as gallbladder signs; the combination points at the gallbladder or the bile duct and is an emergency-department problem, not a message-your-clinic problem.
  • Repeated attacks of pain in the upper right abdomen, often after a heavy meal and often in the evening or at night. The NIH describes attacks that sometimes last several hours, and says more usually follow the first.[19] This is less urgent than the two above but still not something to sit on. It is worth a same-week appointment and an ultrasound.

Ordinary GLP-1 nausea and cramping are common, usually at their peak in the few weeks following each dose step, and they generally settle. We cover that arc separately in how long GLP-1 side effects last. The difference is one of kind, not degree. Routine queasiness is uncomfortable; the pain described above is a reason to be seen.

All four labels agree on one point: where pancreatitis is suspected, the prescriber is told to stop the drug and manage the episode.[1] Zepbound, Mounjaro and Ozempic carry that instruction too.[2] It is a decision for a clinician to make with you. Nothing on this page tells you to stop or continue anything.

Questions worth asking before the first injection

  1. Have I ever had pancreatitis, and does my prescriber know? It was an exclusion criterion in the tirzepatide obesity trials, and it was the single strongest predictor of pancreatitis in the one study that looked for predictors.[6][14]
  2. Do I have gallstones, or have I had them? A history of gallstone disease nearly tripled the odds in that same analysis.[14]
  3. Am I taking this through a seller who will still be reachable at 11pm? A telehealth program with a message queue is not the same thing as an on-call clinician, and abdominal pain does not wait for business hours.
  4. If the product is compounded, who is accountable for it? A compounded preparation has not been FDA-reviewed, so the label facts on this page describe the approved products rather than the vial in your fridge. Our page on whether compounded tirzepatide is safe sets out what that changes and what it does not.

Frequently Asked Questions

The approved labels record acute pancreatitis as something seen in people taking these drugs, which is deliberately not the same as saying the drug produced it. Randomized trial rates are very low and do not clearly separate from placebo. Large database studies disagree with each other: one Veterans Health Administration analysis found a modest increase against an active comparator, and one TriNetX analysis found no increase at all. Anyone who tells you the question is settled is going beyond the evidence in one direction or the other.
That is a decision for a prescriber who knows your history, and it is one they should be told about explicitly. The tirzepatide obesity trials excluded people with a history of pancreatitis, so the strongest evidence base was not built on people like you. In the one study that looked at predictors, a prior episode was the strongest single risk factor for a new one.
Gallstones and gallbladder inflammation occur more often on GLP-1 medication than on placebo in randomized trials, and the effect is larger in trials run for weight loss than in trials run for diabetes. Rapid weight loss is itself a well-established cause of gallstones, which explains a large part of it. The Wegovy label goes further and says the excess persisted even after the degree of weight loss was accounted for.
That is a clinical decision, and we are not going to give you a testing schedule. The labels do say that tirzepatide raised amylase and lipase on average in the trials, and that both manufacturers state the significance of that elevation is unknown in the absence of other symptoms. Interpreting one is a job for whoever ordered it.
The mechanism of the drug does not change, but the accountability does. Everything on this page comes from labels for FDA-approved products and from trials that used them. A compounded preparation has not been reviewed for safety, efficacy or manufacturing quality, so a warning that has been counted for the approved product has not been counted for it.

Related reading on this register: tirzepatide side effects in compounded form, what is known about tirzepatide over the long term, and hair loss and lean mass on GLP-1 medication. Every seller we track carries a dated price on the live price tracker.

References

  1. 1.Novo Nordisk Pharmaceutical Industries, LP WEGOVY (semaglutide) injection, solution; WEGOVY (semaglutide) tablet — prescribing information (SPL SetID ee06186f-2aa3-4990-a760-757579d8f77b) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Eli Lilly and Company ZEPBOUND (tirzepatide) injection, solution — prescribing information (SPL SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  3. 3.Eli Lilly and Company MOUNJARO (tirzepatide) injection, solution — prescribing information (SPL SetID d2d7da5d-ad07-4228-955f-cf7e355c8cc0) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  4. 4.Novo Nordisk Pharmaceutical Industries, LP OZEMPIC (semaglutide) injection, solution — prescribing information (SPL SetID adec4fd2-6858-4c99-91d4-531f5f2a2d79) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  5. 5.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID: 35658024.
  6. 6.Eli Lilly and Company Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities (SURMOUNT-1) — eligibility criteria, NCT04184622 ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT04184622
  7. 7.Eli Lilly and Company A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (SURMOUNT-2) — eligibility criteria, NCT04657003 ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT04657003
  8. 8.Eli Lilly and Company A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-5) — eligibility criteria, NCT05556512 ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT05556512
  9. 9.Novo Nordisk A/S Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT) — eligibility criteria, NCT03574597 ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT03574597
  10. 10.Novo Nordisk A/S Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity (STEP 1) — eligibility criteria, NCT03548935 ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT03548935
  11. 11.Faour O, Boktor M, Yau H, et al. GLP-1 Receptor Agonists Initiation and Risk of Acute Pancreatitis and Pancreatic Cancer: A Real-World Comparative Study. Am J Med Open. 2025. PMID: 41473903.
  12. 12.Nieto LM, Martinez J, Narvaez SI, et al. Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis. Am J Gastroenterol. 2026. PMID: 40358430.
  13. 13.Crisafulli S, Alkabbani W, Paik JM, et al. Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes. Ann Intern Med. 2026. PMID: 41183330.
  14. 14.Postlethwaite R, Amin AM, Alsawas R, et al. Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management. Pancreatology. 2025. PMID: 40695708.
  15. 15.Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med. 2014. PMID: 24571751.
  16. 16.Sodhi M, Rezaeianzadeh R, Kezouh A, et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA (Research Letter). 2023. PMID: 37796527.
  17. 17.He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022. PMID: 35344001.
  18. 18.Zeng Q, Xu J, Mu X, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023. PMID: 37908750.
  19. 19.National Institute of Diabetes and Digestive and Kidney Diseases Symptoms & Causes of Gallstones National Institutes of Health. 2026. https://www.niddk.nih.gov/health-information/digestive-diseases/gallstones/symptoms-causes

Injection Site Reactions: Where Semaglutide and Tirzepatide Really Differ

Semaglutide produced injection site reactions in 1.4% against 1% on placebo. Tirzepatide runs 6–8% against 2%. If you react on one and not the other, that is not your technique.

5 min read

Constipation on a GLP-1: What the Labels Report and What Actually Helps

The Wegovy label reports constipation in 24% against 11% on placebo; the Zepbound label reports it by dose. This explains why it outlasts the nausea and where the confident advice online runs ahead of the evidence.

6 min read

GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026

In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.

7 min read

Ozempic and Gastroparesis: How Real Is “Stomach Paralysis”?

GLP-1 users are diagnosed with gastroparesis more often, about 6.5 per 1,000 a year on semaglutide against 2.1 on another weight drug. What the Ozempic and Mounjaro labels added and when, whether it reverses, and where MDL 3094 stands.

11 min read

Stomach Pain on a GLP-1: What Is Expected and What Is a Warning Sign

Stomach pain on Ozempic, Wegovy, Mounjaro or Zepbound is usually mild and comes with the dose increases. The labels describe the patterns that are not ordinary, and little of the usual advice has been tested.

8 min read

Joint Pain, Back Pain and Aches on a GLP-1: What the Trials Counted

No FDA label for these drugs lists joint or back pain, and in most trials both were about as common on placebo. The exception is the 7.2 mg Wegovy trial, and the one pain the labels do list is in the skin.

8 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

MyDrHank

An oral route if you will not self-inject

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →